Aytu BioPharma, Inc.: Aytu BioPharma Divests U.S. Rights to Natesto to Acerus Pharma
Aytu BioPharma, Inc.: Aytu BioPharma Divests U.S. Rights to Natesto to Acerus Pharma Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with Acerus Pharmaceuticals Corporation (ASP)(ASPCF) whereby Acerus will acquire all remaining rights to Nate...
Source: finanznachrichten.de